炎症性肠病患者感染sars - cov2后呼吸道合胞病毒感染的风险增加：一项倾向匹配的队列分析

IF 3 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Clinical and Translational Gastroenterology Pub Date : 2025-03-27 DOI:10.14309/ctg.0000000000000840

Saqr Alsakarneh, Oscar Ramirez Ramirez, Mary S Hayney, Jana G Hashash, Francis A Farraye, Freddy Caldera

{"title":"炎症性肠病患者感染sars - cov2后呼吸道合胞病毒感染的风险增加：一项倾向匹配的队列分析","authors":"Saqr Alsakarneh, Oscar Ramirez Ramirez, Mary S Hayney, Jana G Hashash, Francis A Farraye, Freddy Caldera","doi":"10.14309/ctg.0000000000000840","DOIUrl":null,"url":null,"abstract":"Introduction: Patients with inflammatory bowel disease (IBD) are at an increased risk of infections. Before the COVID-19 pandemic, respiratory syncytial virus (RSV) followed predictable seasonal patterns, which have been recently disrupted. This study aimed to investigate whether SARS-CoV2 infection is associated with an increased risk of RSV infection in patients with IBD compared to those without a history of SARS-CoV-2.Methods: This retrospective cohort study used the TriNetX database to identify patients aged ≥18 years with IBD and SARS-CoV2 (IBD-SARS-CoV2 cohort) during the 2022 and 2023 RSV seasons. A 1:1 propensity score matching was used to compare patients with IBD but no history of SARS-CoV2 (IBD non-SARS-CoV2 cohort).Results: In the 2022 IBD-SARS-CoV2 cohort (mean age: 53.7 ± 17.6; 59% female; 77% white), the RSV infection risk was 0.47%, higher than 0.19% in the matched IBD non-SARS-CoV2 cohort (aOR: 2.4; 95% CI: 1.5-3.6). The risk was highest 30-60 days post-SARS-CoV2 infection (aOR: 2.9; 95% CI: 1.7-4.9), particularly in those aged ≥60 years (aOR: 2.5; 95% CI: 1.3-4.5). The use of systemic corticosteroids (aOR: 2.3; 95% CI: 1.1-4.6) or immune-modifying therapies (aOR: 3.9; 95% CI: 2-7.1) was associated with higher RSV risk. Similar trends were observed during the 2023 RSV season, with no significant differences in RSV-related hospitalizations.Discussion: Adults with IBD have a higher risk of RSV following SARS-CoV2 infection, particularly those receiving steroids or immune therapies. SARS-CoV2 may have contributed to the recent RSV surge in this population, warranting further research.","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Patients With Inflammatory Bowel Disease Are At Increased Risk Of Respiratory Syncytial Virus Infections post-SARS-CoV2 Infection: A Propensity-Matched Cohort Analysis.\",\"authors\":\"Saqr Alsakarneh, Oscar Ramirez Ramirez, Mary S Hayney, Jana G Hashash, Francis A Farraye, Freddy Caldera\",\"doi\":\"10.14309/ctg.0000000000000840\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Patients with inflammatory bowel disease (IBD) are at an increased risk of infections. Before the COVID-19 pandemic, respiratory syncytial virus (RSV) followed predictable seasonal patterns, which have been recently disrupted. This study aimed to investigate whether SARS-CoV2 infection is associated with an increased risk of RSV infection in patients with IBD compared to those without a history of SARS-CoV-2.Methods: This retrospective cohort study used the TriNetX database to identify patients aged ≥18 years with IBD and SARS-CoV2 (IBD-SARS-CoV2 cohort) during the 2022 and 2023 RSV seasons. A 1:1 propensity score matching was used to compare patients with IBD but no history of SARS-CoV2 (IBD non-SARS-CoV2 cohort).Results: In the 2022 IBD-SARS-CoV2 cohort (mean age: 53.7 ± 17.6; 59% female; 77% white), the RSV infection risk was 0.47%, higher than 0.19% in the matched IBD non-SARS-CoV2 cohort (aOR: 2.4; 95% CI: 1.5-3.6). The risk was highest 30-60 days post-SARS-CoV2 infection (aOR: 2.9; 95% CI: 1.7-4.9), particularly in those aged ≥60 years (aOR: 2.5; 95% CI: 1.3-4.5). The use of systemic corticosteroids (aOR: 2.3; 95% CI: 1.1-4.6) or immune-modifying therapies (aOR: 3.9; 95% CI: 2-7.1) was associated with higher RSV risk. Similar trends were observed during the 2023 RSV season, with no significant differences in RSV-related hospitalizations.Discussion: Adults with IBD have a higher risk of RSV following SARS-CoV2 infection, particularly those receiving steroids or immune therapies. SARS-CoV2 may have contributed to the recent RSV surge in this population, warranting further research.\",\"PeriodicalId\":10278,\"journal\":{\"name\":\"Clinical and Translational Gastroenterology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.14309/ctg.0000000000000840\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ctg.0000000000000840","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

炎症性肠病（IBD）患者感染风险增加。在2019冠状病毒病大流行之前，呼吸道合胞病毒（RSV）遵循可预测的季节性模式，但这种模式最近已被打破。本研究旨在调查与没有SARS-CoV-2病史的IBD患者相比，SARS-CoV2感染是否与RSV感染风险增加相关。方法：本回顾性队列研究使用TriNetX数据库，在2022年和2023年RSV季节识别年龄≥18岁的IBD和SARS-CoV2患者（IBD-SARS-CoV2队列）。采用1:1倾向评分匹配法比较IBD但无SARS-CoV2病史的患者（IBD非SARS-CoV2队列）。结果：在2022年IBD-SARS-CoV2队列中(平均年龄：53.7±17.6；59%的女性;77%白人)，RSV感染风险为0.47%，高于匹配IBD非sars - cov2队列的0.19% (aOR: 2.4；95% ci: 1.5-3.6)。感染sars - cov2后30-60天风险最高(aOR: 2.9；95% CI: 1.7-4.9)，尤其是年龄≥60岁的患者(aOR: 2.5；95% ci: 1.3-4.5)。全身性皮质类固醇的使用(aOR: 2.3；95% CI: 1.1-4.6)或免疫修饰疗法(aOR: 3.9；95% CI: 2-7.1)与RSV风险较高相关。在2023年RSV流行季节也观察到类似的趋势，但与RSV相关的住院率没有显著差异。讨论：患有IBD的成人在感染SARS-CoV2后感染RSV的风险更高，特别是那些接受类固醇或免疫治疗的人。SARS-CoV2可能是导致这一人群中最近RSV激增的原因，值得进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Patients With Inflammatory Bowel Disease Are At Increased Risk Of Respiratory Syncytial Virus Infections post-SARS-CoV2 Infection: A Propensity-Matched Cohort Analysis.

Introduction: Patients with inflammatory bowel disease (IBD) are at an increased risk of infections. Before the COVID-19 pandemic, respiratory syncytial virus (RSV) followed predictable seasonal patterns, which have been recently disrupted. This study aimed to investigate whether SARS-CoV2 infection is associated with an increased risk of RSV infection in patients with IBD compared to those without a history of SARS-CoV-2.

Methods: This retrospective cohort study used the TriNetX database to identify patients aged ≥18 years with IBD and SARS-CoV2 (IBD-SARS-CoV2 cohort) during the 2022 and 2023 RSV seasons. A 1:1 propensity score matching was used to compare patients with IBD but no history of SARS-CoV2 (IBD non-SARS-CoV2 cohort).

Results: In the 2022 IBD-SARS-CoV2 cohort (mean age: 53.7 ± 17.6; 59% female; 77% white), the RSV infection risk was 0.47%, higher than 0.19% in the matched IBD non-SARS-CoV2 cohort (aOR: 2.4; 95% CI: 1.5-3.6). The risk was highest 30-60 days post-SARS-CoV2 infection (aOR: 2.9; 95% CI: 1.7-4.9), particularly in those aged ≥60 years (aOR: 2.5; 95% CI: 1.3-4.5). The use of systemic corticosteroids (aOR: 2.3; 95% CI: 1.1-4.6) or immune-modifying therapies (aOR: 3.9; 95% CI: 2-7.1) was associated with higher RSV risk. Similar trends were observed during the 2023 RSV season, with no significant differences in RSV-related hospitalizations.

Discussion: Adults with IBD have a higher risk of RSV following SARS-CoV2 infection, particularly those receiving steroids or immune therapies. SARS-CoV2 may have contributed to the recent RSV surge in this population, warranting further research.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical and Translational Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

7.00

自引率

0.00%

发文量

114

审稿时长

16 weeks

期刊介绍： Clinical and Translational Gastroenterology (CTG), published on behalf of the American College of Gastroenterology (ACG), is a peer-reviewed open access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology. CTG hopes to fulfill an unmet need for clinicians and scientists by welcoming novel cohort studies, early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines. CTG also welcomes hypothesis-generating small studies, methods papers, and translational research with clear applications to human physiology or disease. Colon and small bowel Endoscopy and novel diagnostics Esophagus Functional GI disorders Immunology of the GI tract Microbiology of the GI tract Inflammatory bowel disease Pancreas and biliary tract Liver Pathology Pediatrics Preventative medicine Nutrition/obesity Stomach.